Praxis NDA review for relutrigine extended 3 months to Dec 27; no new studies required

Filed June 29, 2026 · Period ending June 29, 2026 · ~1 min read

Key Changes

• high

  FDA pushed relutrigine NDA decision date from Sept 27 to Dec 27, 2026, delaying potential commercialization for rare pediatric epilepsies by three months.

  Item 8.01 verify on EDGAR →
• high

  FDA cited no safety or manufacturing concerns and requested no new clinical studies, suggesting core data package and product quality are acceptable.

  Item 8.01 verify on EDGAR →
• medium

  Extension triggered by Praxis submitting additional sensitivity analyses of existing trial data, which FDA classified as a major amendment requiring extra review time.

  Item 8.01 verify on EDGAR →